Abstract
In this review article we have reported a series of hybrid compounds characterized by the presence of a α- halogenocryloyl alkylating moiety of low chemical reactivity, linked to known antitumor agents or their active moieties. Among them, brostallicin (PNU-166196), was selected for clinical development and is now undergoing Phase II studies in patients with advanced or metastatic soft tissue sarcoma.
Keywords: Antitumor agents, Distamycin A, apoptosis, α-bromoacryloyl, hybrid molecules
Mini-Reviews in Medicinal Chemistry
Title: α-Halogenoacrylic Derivatives of Antitumor Agents
Volume: 9 Issue: 1
Author(s): Romeo Romagnoli, Pier Giovanni Baraldi, Olga Cruz-Lopez, Carlota Lopez-Cara and Delia Preti
Affiliation:
Keywords: Antitumor agents, Distamycin A, apoptosis, α-bromoacryloyl, hybrid molecules
Abstract: In this review article we have reported a series of hybrid compounds characterized by the presence of a α- halogenocryloyl alkylating moiety of low chemical reactivity, linked to known antitumor agents or their active moieties. Among them, brostallicin (PNU-166196), was selected for clinical development and is now undergoing Phase II studies in patients with advanced or metastatic soft tissue sarcoma.
Export Options
About this article
Cite this article as:
Romagnoli Romeo, Baraldi Giovanni Pier, Cruz-Lopez Olga, Lopez-Cara Carlota and Preti Delia, α-Halogenoacrylic Derivatives of Antitumor Agents, Mini-Reviews in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/138955709787001640
DOI https://dx.doi.org/10.2174/138955709787001640 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Calixarenes, Cyclodextrins and Fullerenes as New Platforms for Anti-HIV Drug Design: An Overview
Mini-Reviews in Medicinal Chemistry Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry FOXO1: A Potential Target for Human Diseases
Current Drug Targets Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets PET Imaging for Gene & Cell Therapy
Current Gene Therapy Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Biosafety of Lentiviral Vectors
Current Gene Therapy Anthracyclines Still Prove Effective in Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Polyphenols Counteract Tumor Cell Chemoresistance Conferred by Multidrug Resistance Proteins
Anti-Cancer Agents in Medicinal Chemistry Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy Imaging Methods in Gene Therapy of Cancer
Current Gene Therapy Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress
Current Drug Targets Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Dequalinium-Derived Nanoconstructs: A Promising Vehicle for Mitochondrial Targeting
Current Drug Delivery Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention
Current Pharmaceutical Design Complications of Muscle Hematomas in Hemophilia
Cardiovascular & Hematological Disorders-Drug Targets